TY - JOUR T1 - Preliminary Report of Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application JF - medRxiv DO - 10.1101/2021.09.23.21263731 SP - 2021.09.23.21263731 AU - Ebru Erdogan AU - Koray Yalcin AU - Cansu Hemsinlioglu AU - Aslihan Sezgin AU - Utku Seyis AU - Derya Dilek Kancagi AU - Cihan Tastan AU - Bulut Yurtsever AU - Raife Dilek Turan AU - Didem Cakirsoy AU - Selen Abanuz AU - Gozde Sir Karakus AU - Muhammer Elek AU - Huseyin Saffet Bekoz AU - Ali İhsan Gemici AU - Deniz Sargin AU - Mutlu Arat AU - Burhan Ferhanoglu AU - Ebru Pekguc AU - Serdar Ornek AU - Deram Buyuktas AU - Nur Birgen AU - Siret Ratip AU - Ercument Ovali Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/26/2021.09.23.21263731.abstract N2 - Objective Chimeric antigen receptor T (CAR-T) cell therapies already made an impact on the treatment of B cell malignancies. Although CAR-T cell therapies are promising, there are concerns with commercial products regarding their affordability and sustainability. In this preliminary study, results of the first productional and clinical data of academic CAR-T cell (ISIKOK-19) from Turkey are presented.Materials and Methods A pilot clinical trial (NCT04206943) designed to assess the safety and feasibility of ISIKOK-19 T-cell therapy in patients with relapsed and refractory CD19+ tumors was conducted and participating patients received ISIKOK-19 infusions between October 2019 and July 2021. Production data of the first 8 patients and the clinical outcome of 7 patients who received ISIKOK-19 cell infusion is presented in this study.Results Nine patients were enrolled for the trial (ALL n=5 and NHL n=4) but only 7 patients could receive the treatment. Two out of three ALL patients and three out of four NHL patients had complete/partial response (ORR 72%). Four patients (57%) had CAR-T-related toxicities (CRS, CRES, and pancytopenia). Two patients were unresponsive and had progressive disease following CAR-T therapy. Two patients with partial response had progressive disease during follow-up.Conclusion Production efficacy and fulfilling the criteria of quality control were satisfactory for academic production. Response rates and toxicity profiles are acceptable for this heavily pretreated/refractory patient group. ISIKOK-19 cells appear to be a safe, economical, and efficient treatment option for CD19 positive tumors. The findings of this study need to be supported by the currently ongoing clinical trial of ISIKOK-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04206943Funding StatementAll funding in the work was supported by Technology and Innovation Funding Programs Directorate (TEYDEB) and Acibadem Healthcare Group Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Production and treatment protocol was approved by the Ethical Committee of Acibadem University (Approval No: 2019-11/6) and by the review board of the Republic of Turkey Ministery of Health (Approval No:56733164/203)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available via Acibadem Hospital's electronic medical records system. ER -